Abstract
Evaluating bone disease in Gaucher disease is a very important part of monitoring patients on therapy. In the Academic Medical Center (AMC) there is ample experience covering the evaluating of bone marrow involvement. Both state of the art Quantitative Chemical Shift Imaging (QCSI) as well as alternatives have been subject of research protocols. Our experiences are described.
MeSH terms
-
Bone Diseases / drug therapy
-
Bone Diseases / pathology*
-
Disease Progression
-
Drug Monitoring
-
Gaucher Disease / drug therapy
-
Gaucher Disease / pathology*
-
Glucosylceramidase / administration & dosage
-
Glucosylceramidase / therapeutic use
-
Humans
-
Magnetic Resonance Imaging / methods*
-
Magnetic Resonance Spectroscopy
-
Netherlands
-
Recombinant Proteins
Substances
-
Recombinant Proteins
-
Glucosylceramidase
-
imiglucerase